A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Alterome Therapeutics, Inc.
Pfizer
Tizona Therapeutics, Inc
Revolution Medicines, Inc.
University of California, Davis
Masonic Cancer Center, University of Minnesota
SWOG Cancer Research Network